

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231

APPLICATION NO./CONTROL NO. FILING DATE FIRST NAMED INVENTOR /PATENT IN REEXAMINATION ATTORNEY DOCKET NO. 109800863 03/07/2001 Busby et al. 109272.148

EXAMINER

David A. Lambertson

ART UNIT

PAPER

1636

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the one month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **David A**. **Lambertson** whose telephone number is (703)-308-8365.

Specifically concerning this application, the application contains sequences that are identified by SEQ ID NOS, but does not contain a paper copy of the sequence listing in the application. Additionally, applicant does not appear to have submitted a CRF of the sequence listing.

REMY YUCEL, PH.D SUPERVISORY PATENT EXAMINER

Remephas

TECHNOLOGY CENTER 1600